Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to compare the antiplaque efficacy of a 0,12% chlorhexidine and 0,05% cetyl-pyridinium chloride mouth rinse (Perio-aid®) with a 0,2% chlorhexidine non-alcohol base mouth rinse (Corsodyl Care®).


Clinical Trial Description

Dental plaque is a bacterial biofilm adhering to the tooth surfaces and is not the same in the different areas of the tooth: there is the supragingival, the plaque from the gingival margin and subgingival plaque. It is mainly composed of complex bacterial populations organized in a carbohydrate matrix also containing a small number of epithelial cells, leukocytes, macrophages and inorganic components such as calcium and phosphorus. This biofilm develops in virtually all places where there are damp surfaces and teeth are a very stable support for bacterial colonization. Mechanical oral hygiene procedures such as tooth brushing, dental flossing and inter-dental brushing is the most effective method for plaque removal but mouth rinses containing anti-microbials play an important role in maintaining oral health.

Chlorhexidine (CHX) digluconate, a cationic biguanide, is known to be an effective anti-plaque and anti-inflammatory agent and is the gold standard in chemical plaque control. The benefits of CHX are based on the high intra-oral substantivity and its bactericidal and bacteriostatic activities. This ingredient, when delivered orally, is free from systemic toxicity and microbial resistance, and supra-infections do not occur. It has been proven in several "in vitro" and "in vivo" studies, the safety and long-term efficacy of CHX mouth rinses. There have been suggested many indications for the use of this antiseptic and plaque control is one of the most important factors for proper healing after periodontal surgery and implant therapy.

The 0.2% CHX solution became the standard international concentration, due to his development in Europe but similar levels of plaque inhibition can be achieved with larger volumes of lower concentration solutions of CHX.

A lower concentration of CHX (0.12%) has been tested in several studies and has also been shown to confer clinical benefits. More important than the concentration of CHX seems to be the dose which balances efficacy against local side effects and user acceptability. The optimum dose is considered to be about 20 mg twice daily.

Clinically, the 0,12% CHX have been found to be similarly effective as 0.2% if the volume of the rinse was increased from 10 to 15 ml, yielding an 18 mg dose on each occasion but with respect to plaque growth inhibition, there is a small but significant difference in favour of the 0.2% CHX concentration.

CHX mouthrinses can have a variety of side effects and the most common, according to the manufacturers of these products, are loss of taste, tongue burning and irritation of the oral mucosa. Some brands have lowered the concentration of CHX in their mouthrinses and removed the ethanol in order to eliminate side effects such as soreness and to improve acceptability. A study concluded that the perturbation of taste perception after using 0.12% CHX is significantly lower than that after using 0.2% CHX. On the other hand, another studies concluded that there was no significant difference in terms of taste perception.

This study was a double-blinded, randomized two group parallel, to compare the antiplaque efficacy of two mouth rinses, during a 3-day plaque accumulation model, in periodontal healthy patients. After supragingival prophylaxis participants rinsed twice a day over a 72h non-brushing period. Primary outcome variable was plaque index. As secondary outcomes the taste and side effects variables were studied. Mann-Whitney, χ2 and Fisher's Exact tests were used to compare the variables ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01580943
Study type Interventional
Source Universidade do Porto
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 2011
Completion date March 2012

See also
  Status Clinical Trial Phase
Completed NCT04881357 - Antiplaque/Antigingivitis Effect of Lacer Oros Integral N/A
Completed NCT04561960 - Efficacy of Miswak in Oral Hygiene Maintenance Phase 4
Completed NCT04025684 - Efficacy of Manual Toothbrushes in Removing Dental Plaque N/A
Completed NCT03394729 - Effect of a Propolis Tablet on the Saliva and the Amount of Adolescent Dental Plaque Microbes Phase 2/Phase 3
Completed NCT05187507 - Effectiveness of Theobromine Toothpaste N/A
Completed NCT04485520 - Efficacy of the Extract of Carica Papaya as an Inhibitor of Streptococcus Mutans N/A
Completed NCT02884817 - Essential Oil+ELA, Plaque and Gingivitis Phase 4
Completed NCT02552589 - Effect of Toothpaste on the Reduction of Plaque and Inflammation N/A
Completed NCT02194023 - Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%. Phase 2
Completed NCT01237782 - Efficacy of a Propolis-based Denture Cleanser N/A
Completed NCT00758394 - Clinical Study to Compare Dental Plaque Control Phase 3
Completed NCT00254345 - Effect of Provisional-Crown Surface Coating on Biofilm Formation Phase 1
Completed NCT05579938 - Effect of Enzymes on Dental Biofilm Accumulation N/A
Completed NCT05038293 - Efficacy of Plaque Removal of a Novel Brushing Device N/A
Terminated NCT05082103 - Effect of Enzymes on Dental Biofilm Accumulation in Healthy Individuals N/A
Not yet recruiting NCT06081868 - RCT on Effectiveness of Oral Health Preventive Programmes in School Children in Uganda N/A
Completed NCT05853679 - Regular Antibacterial Photodynamic Therapy on Oral Hygiene in Elderly Residents N/A
Completed NCT05521230 - Short-Term Anti-plaque Effect of Cymenol Mouthwash Analysed Using Dentius Deep Plaque Software Phase 1
Completed NCT03311438 - Oral Health Intervention Program for Children With Congenital Heart Defects N/A
Enrolling by invitation NCT06122636 - Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC N/A